Persius/hicric huggingface dataset:
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules state that no payment may be made for the implantation of dorsal column or depth brain stimulators 
or services and supplies related to such implantation, unless all of the conditions listed below have been met: 
 
1.The implantation of the stimulator is used only as a late resort (if not a last resort) for patients with chronic 
intractable pain, 
2. With respect to item a, other treatment modalities have been tried and did not prove satisfactory, or are 
judged to be unsuitable or contraindicated for the given patient, 
3. Patients have undergone careful screening, evaluation and diagnosis by a multidisciplinary team prior to 
implantation, 
4. All the facilities, equipment, and professional and support personnel required for the proper diagnosis, 
treatment training, and follow up of the patient must be available and, 
5. Demonstration of pain relief with a temporarily implanted electrode precedes permanent implantation. 
 
You can find this information in the National Coverage Determination (NCD): Electrical Nerve Stimulators 
160.7. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules state that FDA-approved hypoglossal nerve neurostimulation is considered medically reasonable and 
necessary for the treatment of moderate to severe obstructive sleep apnea when all of the following criteria are 
met: 
1. Beneficiary is 22 years of age or older; and 
2. Body mass index (BMI) is less than 35 kg/m
2
; and 
3. A polysomnography (PSG) is performed within 24 months of first consultation for HGNS implant; and 
4. Beneficiary has predominantly obstructive events (defined as central and mixed apneas less than 25% 
of the total AHI); and 
5. AHI is 15 to 65 events per hour; and 
6. Beneficiary has documentation that demonstrates CPAP failure (defined as AHI greater than 15 despite 
CPAP usage) or CPAP intolerance (defined as less than 4 hours per night, 5 nights per week or the 
CPAP has been returned) including shared decision making that the patient was intolerant of CPAP 
despite consultation with a sleep expert; and 
7. Absence of complete concentric collapse at the soft palate level as seen on a drug-induced sleep 
endoscopy (DISE) procedure; and 
8. No other anatomical findings that would compromise performance of device (e.g., tonsil size 3 or 4 per 
standardized tonsillar hypertrophy grading scale). 
 
The following are considered not reasonable and necessary and therefore will be denied: 
1. Use for all other indications. 
2. Non-FDA-approved hypoglossal nerve neurostimulation. 
3. Presence of any of the following: 
 Beneficiaries with central and mixed apneas that make up more than one-quarter of the total 
AHI. 
 Beneficiaries with an implantable device could experience unintended interaction with the 
HGNS implant system. Limitations are: 
a. BMI equal to or greater than 35 
b. Neuromuscular disease affecting the respiratory system c. Hypoglossal-nerve palsy 
d. Severe restrictive or obstructive pulmonary disease 
e. Moderate-to-severe pulmonary arterial hypertension 
f. Severe valvular heart disease 
g. New York Heart Association class III or IV heart failure 
h. Recent myocardial infarction or severe cardiac arrhythmias (within the past 6 months) 
i. Persistent uncontrolled hypertension despite medication use 
j. An active, serious mental illness that reduces the ability to carry out Activities of Daily 
Living (ADLs) and would interfere with the patients ability to operate the HNS and 
report problems to the attending provider 
k. Coexisting nonrespiratory sleep disorders that would confound functional sleep 
assessment 
 
You can find these rules in Local Coverage Determination (LCD) Hypoglossal Nerve Stimulation for the 
Treatment of Obstructive Sleep Apnea (L38387). 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say a health plan must disclose to its enrollees in clear, accurate terms all cost sharing information 
(such as copayments, deductibles, and coinsurance). You can find this rule at 42 CFR Section 422.111(a) and 
(b). 
 
The rules say that a copayment is a fixed amount charged to an enrollee on a per-service basis. The rules say 
that coinsurance is a fixed percentage of the total amount paid for a health care service that can be charged to 
an enrollee on a per-service basis. You can find this rule at 42 CFR Section 422.2.  
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The Plan 
contract says that enrollees must pay a $25 copayment for each Medicare-covered occupational therapy visit. 
You can find this information on page 65 of the Plans 2023 Evidence of Coverage (EOC). 
 
The plan contract also says that enrollees must pay a $295 copayment for each Medicare-covered outpatient 
surgery in an outpatient hospital. You can find this information on page 66 of the Plans 2023 Evidence of 
Coverage EOC.
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that medically necessary services are those that are reasonable and necessary for the diagnosis or 
treatment of an illness or injury. Medically necessary services include services to improve the functioning of a 
malformed body member. You can find this rule in the Social Security Act, Section 1862(a)(1)(A). 
 
The rules say that services that are not medically necessary are not covered. The rules also say that 
experimental and investigational devices are not covered. You can find this rule at 42 CFR Sections 411.15 and 
411.15(o). 
 
The rules say that Polyethylene-glycol (PEG) hydrogel is covered once in patients with clinically localized 
prostate cancer who meet specific coverage criteria and do not meet any of the following exclusion criteria: 
     1. Less than 5-year life-expectancy and asymptomatic 
     2. Prior prostate cancer treatment (surgery or radiation therapy) 
     3. Active bleeding disorder or clinically significant coagulopathy 
     4. Active inflammatory or infectious disease in the perineum or injection area (e.g., prostatitis, anorectal  
         irritable bowel disease) 
     5. Prostate volume greater than 80 cc 
 
You can find this information in the Centers for Medicare & Medicaid Services, Local Coverage Determination 
(LCD): Prostate Rectal Spacers (L37485). 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that the provider, supplier, or beneficiary, as appropriate, must furnish to the intermediary or 
carrier sufficient information to determine whether payment is due and the amount of payment. You can find 
this rule at 42 CFR 424.5. 
 
The rules say for Medicare to consider coverage and payment for any item or service, the information 
submitted by the supplier or provider must corroborate the documentation in the beneficiary's medical 
documentation and confirm that Medicare coverage criteria have been met. You can see this in the Centers for 
Medicare & Medicaid Services, Internet Only Manual, Publication 100-08, Medicare Program Integrity 
Manual, Chapter 3, Section 3.3.2.1. 
 
The rules say beginning January 1, 2022, home health agencies (HHAs) will no longer submit Requests for 
Anticipated Payment (RAPs). Instead, for each admission to home health the HHA notifies Medicare systems 
via submission of a Notice of Admission (NOA). The NOA is a one-time submission to establish that the 
beneficiary is under a home health period of care and trigger home health consolidated billing edits. The NOA 
covers contiguous 30-day periods of care until the individuals is discharged from Medicare home health 
services.  
 
All HHAs must submit an NOA to their Medicare contractor within 5 calendar days from the start of care date 
to establish that the beneficiary is under a Medicare home health period of care and also to trigger home health 
consolidated billing edits. In instances where an NOA is not timely-filed, Medicare shall reduce the payment 
for a period of care, including outlier payments, by the number of days from the home health admission date 
until the date the NOA is submitted to, and accepted by, the contractor, divided by 30. This reduction shall be a 
provider liability, and the provider shall not bill the beneficiary for it. You can find this information in the 
Centers for Medicare & Medicaid Services, Internet-Only Manual, Publication 100-02, Medicare Benefit 
Policy Manual, Chapter 7, Section 10.4.  
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that for coverage of left atrial appendage closure (LAAC), the patient must have: 
 
- A CHADS2 score greater than or equal to 2 (Congestive heart failure, Hypertension, Age greater than 
75, Diabetes, Stroke/transient ischemia attack/thromboembolism) or CHA2DS2-VASc score greater than or 
equal to 3 (Congestive heart failure, Hypertension, Age greater than or equal to 65, Diabetes, Stroke/transient 
ischemia attack/thromboembolism, Vascular disease, Sex category) 
- A formal shared decision-making interaction with an independent non-interventional physician using an 
evidence-based decision tool on oral anticoagulation in patients with NVAF prior to LAAC. Additionally, the 
shared decision-making interaction must be documented in the medical record. 
- A suitability for short-term warfarin but deemed unable to take long-term oral anticoagulation following 
the conclusion of shared decision making, as LAAC is only covered as a second line therapy to oral 
anticoagulants. The patient (preoperatively and postoperatively) is under the care of a cohesive, 
multidisciplinary team (MDT) of medical professionals. The procedure must be furnished in a hospital with an 
established structural heart disease (SHD) and/or electrophysiology (EP) program. 
 
You can find this information in the Centers for Medicare & Medicaid Services, Internet-Only Manual, 
Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Section 20.34. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that Medicare may cover a drug or biological if it is safe and effective and otherwise reasonable 
and necessary. You can find this rule in the Centers for Medicare & Medicaid Services, Internet Only Manual, 
Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 50.4.1. 
  
Medicare rules also allow the plan to use step therapy. This is the process of beginning drug therapy for a 
medical condition with "preferred" (or more cost-effective) on-formulary drug alternative(s) and progressing to 
other drug therapies only as necessary. A plan must grant an exception to its step therapy rules if it determines 
that the requested drug is medically necessary, consistent with the prescriber's statement. The statement must 
show that the step therapy drugs: have been ineffective in treating the enrollee; or are likely to be ineffective or 
adversely affect the drug's effectiveness or patient compliance; or are likely to cause an adverse reaction or 
other harm to the enrollee.  
 
Medicare Advantage plans should ensure that new step therapy requirements do not disrupt ongoing Part B 
drug therapies for enrollees. Step therapy may only be applied to new prescriptions or administrations of Part B 
drugs for enrollees that are not actively receiving the affected medication. You can find this information at 42 
CFR Sections 422.2 and 422.136. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The contract 
says that the Plan has step therapy requirements for certain Medicare Part B covered drugs/biologicals. 
Enrollees may be required to try a preferred drug before the Plan will approve the requested medication. You 
can find this information on page A1-35 and A1-36 of the 2024 Evidence of Coverage
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that Medicare will not pay for dental services. Dental services are items and services involving 
the care, treatment, filling, removal or replacement of teeth or structures directly supporting the teeth. Medicare 
defines "structures directly supporting the teeth" as the periodontium, which includes the gingivae, 
dentogingival junction, periodontal membrane, cementum of the teeth, and alveolar process. You can find this 
rule in the Social Security Act, Section 1862(a)(12) and in the Centers for Medicare & Medicaid Services, 
Internet Only Manual, Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 150. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The contract 
says that the Plan covers certain dental services as a supplemental (extra) benefit. This benefit includes 
preventive and comprehensive services. The dental savings Plan is excluded from this benefit. You can find 
this information on pages 62-65 of the Plans 2023 Evidence of Coverage (EOC).
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that Medicare will not pay for dental services. Dental services are items and services involving 
the care, treatment, filling, removal or replacement of teeth or structures directly supporting the teeth. Medicare 
defines "structures directly supporting the teeth" as the periodontium, which includes the gingivae, 
dentogingival junction, periodontal membrane, cementum of the teeth, and alveolar process. You can find this 
rule in the Social Security Act, Section 1862(a)(12) and in the Centers for Medicare & Medicaid Services, 
Internet Only Manual, Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 150. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The contract 
says that the Plan covers certain dental services as a supplemental (extra) benefit. This benefit does not include 
endosteal implants (D6010), removal of impacted tooth (D7240), and grafts of the mandible or maxilla 
(D7950). You can find this information on pages 4-59 to 4-68 of the Plans 2022 Evidence of Coverage (EOC).
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules state that effective for services performed on or after January 27, 2020, Medicare has determined that 
next generation sequencing (NGS) as a diagnostic laboratory test is reasonable and necessary and covered 
nationally for patients with germline (inherited) cancer, when performed in a Clinical Laboratories 
Improvement Amendments (CLIA)-certified laboratory, when ordered by a treating physician and when all of 
the following requirements are met: 
a. Patient has: 
i. ovarian or breast cancer; and, 
ii. a clinical indication for germline (inherited) testing for hereditary breast or ovarian cancer; and, 
iii. a risk factor for germline (inherited) breast or ovarian cancer; and 
iv. not been previously tested with the same germline test using NGS for the same germline genetic 
content. 
b. The diagnostic laboratory test using NGS must have all of the following: 
i. Food & Drug Administration (FDA)-approval or clearance; and, 
ii. results provided to the treating physician for management of the patient using a report template 
to specify treatment options. 
 
You can find these rules in National Coverage Determination (NCD) Next Generation Sequencing (NGS) 
(90.2). 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that a Medicare plan may restrict members to a network of providers as long as medically 
necessary covered care is accessible and available through this network. The rules say that the Plan must 
arrange for and cover any medically necessary covered benefit of the plan provider network, but at in-network 
cost sharing, when an in-network provider or benefit is unavailable or inadequate to meet a member's medical 
needs. You can find this rule at 42 CFR Section 422.112(a)(1)(iii). 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The Plan 
contract says that, with limited exceptions, members of the Plan must use network providers to get medical care 
and services. The only exceptions are emergencies, urgently needed care when the network is not available 
(generally, when the enrollee is out of the area), out-of-area dialysis services, and cases in which the Plan 
authorizes the use of out-of-network providers. As a member of our plan, you can choose to receive care from 
out-of-network providers for routine dental services only. You can find this information on pages 31 of the 
Plan's 2024 Evidence of Coverage (EOC).
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules state that coverage is provided for multi-gene non-next generation sequencing (NGS) panel testing 
and NGS testing for the diagnostic workup for myeloproliferative disease (MPD), also known as 
myeloproliferative neoplasms (MPNs), and limited coverage for single-gene testing of patients with BCR-ABL 
negative MPD. BCR-ABL negative MPD includes polycythemia vera (PV), essential thrombocythemia (ET), 
and primary myelofibrosis (PMF). 
 
For laboratories performing single gene technologies, a sequential genetic testing approach is expected. Once a 
positive result is obtained and the appropriate diagnosis is established, further testing should stop. Reflex 
testing to the next gene will be considered reasonable and necessary if the following sequence of genetic tests 
produce a negative result: 
 
1. BCR-ABL negative test results, progress to #2 
2. JAK 2, cv negative test results, progress to #3 or #4 
3. JAK, exon 12 (JAK2 exon 12 is only done when PV is suspected) 
4. Calreticulin (CALR)/MPL (CALR/MPL is only done when either ET or PMF is suspected; testing for 
CALR/MPL does NOT require a negative JAK2 exon 12, just a negative JAK2 V617F result) 
 
Genetic testing of the JAK2 V617F mutation is medically necessary when the following criteria are met: 
 
-Genetic testing impacts medical management; and  
-Patient would meet World Health Organizations (WHO) diagnostic criteria for myeloproliferative disease if 
JAK2 V617F were identified. 
 
Genetic testing of JAK2 exon 12, performed to identify PV, is medically necessary when the following criteria 
are met: 
 
-Genetic testing impacts medical management; and 
-Patient would meet WHOs diagnostic criteria for PV, if JAK2 exon 12 testing were positive; and 
-JAK2 V617F mutation analysis was previously completed and was negative.  
You can find this information Local Coverage Determination (LCD): MolDX: Genetic Testing for BCR-ABL 
Negative Myeloproliferative Disease (L36815). 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say a health plan must disclose to its enrollees in clear, accurate terms all cost sharing information 
(such as copayments, deductibles and coinsurance). You can find this rule at 42 CFR Section 422.111(a) and 
(b).  
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The Plan 
contract also says that there is a $200 deductible and a 10% coinsurance which applies to certain items and 
services. The Plan deductible applies to Medicare Part B prescription drugs and outpatient surgeries. You can 
find this information on page 1, on page 32 and on page 43 of the Plan's 2022 Evidence of Coverage (EOC).